Pacira Pharmaceuticals Inc FDA Recalls

2 recalls on file across drugs, 0 of them Class I and 2 still open. This firm is not matched to a listed company.

Newest first

Class I is the FDA's most serious grade: a reasonable probability of serious harm or death.

Product	Reason	Class	Initiated
Zilretta (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, Manufactured for: PaClass IIJun 12, 2024Failed Dissolution Specifications - did not meet the accept	Failed Dissolution Specifications - did not meet the acceptance criteria for IVR Level 3 testing at 9 months	Class IIDrugs	Jun 12, 2024
Drug Vial Label: Zilretta¿ (triamcinolone acetonide extended-release injectable suspension), 32 mg per vial, Rx only, MaClass IIMay 7, 2024Failed Stability Specifications - at 12 months 2-8 degrees C	Failed Stability Specifications - at 12 months 2-8 degrees C followed by 6 weeks at 25 degrees C.	Class IIDrugs	May 7, 2024